Moderna Inc. [NASDAQ: MRNA] traded at a high on 01/26/23, posting a 0.09 gain after which it closed the day’ session at $193.24. The company report on January 17, 2023 that Moderna Announces mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine, Has Met Primary Efficacy Endpoints in Phase 3 Trial in Older Adults.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
mRNA-1345 demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults.
mRNA-1345 was generally well-tolerated, with no safety concerns identified by the DSMB.
The results of the trading session contributed to over 2387371 shares changing hands. Over the past one week, the price volatility of Moderna Inc. stands at 3.08% while the volatility over the past one month is 4.54%.
The market cap for MRNA stock reached $72.86 billion, with 390.00 million shares outstanding and 346.94 million shares in the current float. Compared to the average trading volume of 5.21M shares, MRNA reached a trading volume of 2387371 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Moderna Inc. [MRNA]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRNA shares is $224.87 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRNA stock is a recommendation set at 2.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Jefferies have made an estimate for Moderna Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 19, 2022. While these analysts kept the previous recommendation, Chardan Capital Markets raised their target price from $186 to $191. The new note on the price target was released on December 14, 2022, representing the official price target for Moderna Inc. stock. Previously, the target price had yet another drop from $174 to $101, while SVB Leerink kept a Mkt Perform rating on MRNA stock.
The Average True Range (ATR) for Moderna Inc. is set at 9.04, with the Price to Sales ratio for MRNA stock in the period of the last 12 months amounting to 3.41. The Price to Book ratio for the last quarter was 4.19, with the Price to Cash per share for the same quarter was set at 22.14. Price to Free Cash Flow for MRNA in the course of the last twelve months was 11.75 with Quick ratio for the last quarter at 1.80.
How has MRNA stock performed recently?
Moderna Inc. [MRNA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.50. With this latest performance, MRNA shares dropped by -2.93% in over the last four-week period, additionally plugging by 22.29% over the last 6 months – not to mention a rise of 26.68% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRNA stock in for the last two-week period is set at 54.27, with the RSI for the last a single of trading hit 54.19, and the three-weeks RSI is set at 54.61 for Moderna Inc. [MRNA]. The present Moving Average for the last 50 days of trading for this stock 186.04, while it was recorded at 194.80 for the last single week of trading, and 155.46 for the last 200 days.
Moderna Inc. [MRNA]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Moderna Inc. [MRNA] shares currently have an operating margin of +71.89 and a Gross Margin at +84.53. Moderna Inc.’s Net Margin is presently recorded at +66.27.
Return on Equity for this stock inclined to 146.08, with Return on Assets sitting at 75.78.
Moderna Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.80 and a Current Ratio set at 2.10.
Insider trade positions for Moderna Inc. [MRNA]
There are presently around $46,949 million, or 65.90% of MRNA stock, in the hands of institutional investors. The top three institutional holders of MRNA stocks are: BAILLIE GIFFORD & CO with ownership of 44,786,746, which is approximately -1.089% of the company’s market cap and around 2.40% of the total institutional ownership; VANGUARD GROUP INC, holding 27,442,158 shares of the stock with an approximate value of $5.3 billion in MRNA stocks shares; and BLACKROCK INC., currently with $4.91 billion in MRNA stock with ownership of nearly -3.11% of the company’s market capitalization.
Positions in Moderna Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 419 institutional holders increased their position in Moderna Inc. [NASDAQ:MRNA] by around 14,152,178 shares. Additionally, 473 investors decreased positions by around 12,313,804 shares, while 176 investors held positions by with 216,491,547 shares. The mentioned changes placed institutional holdings at 242,957,529 shares, according to the latest SEC report filing. MRNA stock had 115 new institutional investments in for a total of 2,975,641 shares, while 118 institutional investors sold positions of 1,109,305 shares during the same period.